HB1290 (2022) Detail

Establishing a task force on precision medicine and biomarker testing.


HB 1290-FN - AS INTRODUCED

 

 

2022 SESSION

22-2677

05/04

 

HOUSE BILL 1290-FN

 

AN ACT establishing a task force on precision medicine and biomarker testing.

 

SPONSORS: Rep. Rogers, Merr. 28

 

COMMITTEE: Health, Human Services and Elderly Affairs

 

-----------------------------------------------------------------

 

ANALYSIS

 

This bill establishes a task force on precision medicine and biomarker testing.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

22-2677

05/04

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Twenty Two

 

AN ACT establishing a task force on precision medicine and biomarker testing.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  Findings. The legislature finds that 60 percent of medical treatments in preclinical development rely on biomarker data.  In fact, biomarker testing is available for an ever-increasing range of conditions and diseases, but patient access to these tests is not keeping pace with the rate of innovation and a lack of awareness among providers and patients, a lack of common terminology, and deficient coverage policies by both public and private payers are preventing effective adoption and integration of biomarker testing.

2  New Section; Task Force on Precision Medicine and Biomarker Testing.  Amend RSA 126-A by inserting after section 15-a the following new section:

126-A:15-b  Task Force on Precision Medicine and Biomarker Testing.

I.  The health and human services oversight committee, established in RSA 126-A:13, shall convene a precision medicine and biomarker testing task force.

II.  The task force shall study and make recommendations to the legislature to support improved awareness, understanding, and access to precision medicine and biomarker testing by patients, health care providers, employers, and public and private payers.

III.  The task force shall be comprised of the following members, appointed in accordance with this paragraph:

(a)  The oversight committee shall jointly appoint:

(1)  One representative of an academic medical center conducting research on biomarker testing and/or personalized medicine.

(2)  One expert who is a researcher in molecular diagnostics/ biomarker testing.

(3)  One molecular pathologist.

(4)  One expert who is a health care provider who utilizes biomarker tests to diagnose, treat and/or monitor patients.

(b)  House members of the oversight committee shall appoint:

(1)  One health technology researcher who specializes in personalized medicine.

(2)  One representative of a patient advocacy organization.

(3)  One representative of a diagnostic company such as a reference laboratory or biomarker test manufacturer.

(c)  Senate members of the oversight committee shall appoint:

(1)  One representative of a health insurance plan or employer that is self-insured.

(2)  One representative of a national organization which publishes clinical guidelines on biomarker testing and/or personalized medicine or their appointee.

(3)  One member of a community or community organization impacted by health inequities related to biomarker testing and/or precision healthcare.

(d)  The commissioner of the department of health and human services, or the commissioner’s designee, shall serve as an ex-officio member of the task force.

(e)  The oversight committee shall jointly select the chairperson of the task force.

IV.  The task force shall:

(a)  Solicit definitions of “biomarker testing,” “precision medicine,” and “molecular testing,” and any other terms as determined by the task force.

(b)  Review reports or studies on the current status of precision medicine and biomarker testing, how the science is evolving, and patients’ and providers’ experiences in accessing and providing biomarker testing and personalized health care.

(c)  Examine barriers to the use of biomarker testing across the continuum of consumer and patient needs focused on diagnosis, treatment decisions, and post-treatment monitoring of disease, including but not limited to: lack of awareness of biomarker tests generally, inconsistency of terminology, no or low reimbursement for providers, lack of coverage or restrictive utilization management by payers, and level of patient and provider understanding of the use of biomarker testing in measuring indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention.

(d)  Study the role of clinical practice guidelines in health care provider and payer decision making related to biomarker testing, especially when evidence-based tests are available, but clinical guidelines are not yet developed.

(e)  Identify opportunities to expand awareness, education, understanding and usefulness of biomarker testing and precision medicine to improve care and reduce unnecessary health care spending.

(f)  Make and report findings for policies or actions to improve awareness, education, and coverage that would optimize the use of biomarker testing and precision medicine for residents of New Hampshire.

V.  The task force may:

(a)  Establish subcommittees as necessary to fulfill its duties.

(b)  Solicit expert testimony to fulfill its duties.

VI.  A member or an ex officio member of the task force shall not receive compensation as a member of the task force; but shall receive mileage at the rate paid to state employees when attending to the duties of the task force.

VII.  On or before November 1, 2024, the task force shall submit a report of its findings and recommendations to the governor and legislature.

3  Repeal.  RSA 126-A:15-b, relative to the task force on precision medicine and biomarker testing, is repealed.

4  Effective Date.

I.  Section 3 of this act shall take effect November 1, 2024.

II.  The remainder of this act shall take effect upon its passage.

 

LBA

22-2677

10/18/21

 

HB 1290-FN- FISCAL NOTE

AS INTRODUCED

 

AN ACT establishing a task force on precision medicine and biomarker testing.

 

FISCAL IMPACT:

The Legislative Budget Assistant has determined that this legislation, as introduced, has a total fiscal impact of less than $10,000 in each of the fiscal years 2022 through 2025.

 

AGENCIES CONTACTED:

None

 

Links


Date Body Type
Feb. 15, 2022 House Hearing
March 7, 2022 House Exec Session
House Floor Vote

Bill Text Revisions

HB1290 Revision: 33985 Date: Nov. 19, 2021, 2:26 p.m.

Docket


Oct. 19, 2022: Interim Study Report: Not Recommended for Future Legislation (Vote 17-0)


May 24, 2022: Interim Study Work Session: 06/06/2022 09:30 am LOB 201-203


March 15, 2022: Refer for Interim Study: MA VV 03/15/2022 HJ 6


March 9, 2022: Committee Report: Refer for Interim Study (Vote 20-0; CC)


March 1, 2022: Executive Session: 03/08/2022 09:30 am LOB 210-211


Feb. 3, 2022: Public Hearing: 02/15/2022 09:30 am LOB 210-211


Nov. 19, 2021: Introduced 01/05/2022 and referred to Health, Human Services and Elderly Affairs